BI
BVF Inc Portfolio holdings
AUM
$2.8B
This Quarter Return
+19.15%
1 Year Return
+17.96%
3 Year Return
+404.14%
5 Year Return
+563.41%
10 Year Return
+5,885.83%
AUM
$2.8B
AUM Growth
+$2.8B
(+14%)
Cap. Flow
-$238M
Cap. Flow
% of AUM
-8.49%
Top 10 Holdings %
Top 10 Hldgs %
76.91%
Holding
52
New
1
Increased
5
Reduced
8
Closed
8
Top Buys
| 1 |
Protagonist Therapeutics
PTGX
|
$35.2M |
| 2 |
Immunocore
IMCR
|
$32.1M |
| 3 |
Kymera Therapeutics
KYMR
|
$14.9M |
| 4 |
Verastem
VSTM
|
$5.41M |
| 5 |
TScan Therapeutics
TCRX
|
$488K |
Top Sells
| 1 |
CBIO
Crescent Biopharma, Inc. Common Stock
CBIO
|
$132M |
| 2 |
RAPT Therapeutics
RAPT
|
$64.7M |
| 3 |
Galapagos
GLPG
|
$36.5M |
| 4 |
VERV
Verve Therapeutics
VERV
|
$31.6M |
| 5 |
iTeos Therapeutics
ITOS
|
$18.4M |
Sector Composition
| 1 | Healthcare | 99.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Eledon Pharmaceuticals
ELDN
$155M
| $17.1M | 0.61% | 6,293,282 | – | – |
|
27
Annexon
ANNX
$226M
| $16.8M | 0.6% | 7,000,000 | – | – |
|
|
PVLA
28
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $15.7M | 0.56% | 696,555 | – | – |
|
29
ESSA Pharma
EPIX
$11.4M
| $14.9M | 0.53% | 8,748,629 | – | – |
|
30
Repare Therapeutics
RPTX
$71.7M
| $14.4M | 0.51% | 10,333,600 | – | – |
|
|
31
Verastem
VSTM
$569M
| $14.1M | 0.5% | 3,404,425 +1,303,957 | +62% | +$5.41M |
|
|
32
RAPT Therapeutics
RAPT
$188M
| $9.24M | 0.33% | 1,154,692 -8,082,864 | -88% | -$64.7M |
|
33
Forte Biosciences
FBRX
$137M
| $7.61M | 0.27% | 588,344 -5,938 | -1% | -$76.8K |
|
|
34
TScan Therapeutics
TCRX
$102M
| $7.58M | 0.27% | 5,226,074 +336,600 | +7% | +$488K |
|
|
IMA
35
ImageneBio, Inc. Common Stock
IMA
$150M
| $5.37M | 0.19% | 4,006,564 | – | – |
|
36
Immunic
IMUX
$80.9M
| $5.34M | 0.19% | 7,652,972 -1,250,000 | -14% | -$872K |
|
|
MOLN
37
Molecular Partners
MOLN
$140M
| $5.19M | 0.19% | 1,353,968 | – | – |
|
38
Avalo Therapeutics
AVTX
$122M
| $5.13M | 0.18% | 1,028,049 -8,630 | -0.8% | -$43.1K |
|
|
IVA
39
Inventiva
IVA
$861M
| $2.14M | 0.08% | 686,040 | – | – |
|
40
Tenax Therapeutics
TENX
$27.3M
| $1.98M | 0.07% | 339,549 | – | – |
|
41
SAB Biotherapeutics
SABS
$19.3M
| $1.61M | 0.06% | 917,826 | – | – |
|
42
Ovid Therapeutics
OVID
$91M
| $1.27M | 0.05% | 3,853,818 | – | – |
|
43
enGene Holdings Inc. Warrants
ENGNW
$7.08M
| $586K | 0.02% | 945,402 | – | – |
|
44
NLS Pharmaceutics
NLSP
$10.4M
| $417K | 0.01% | 143,676 | – | – |
|
|
ALLK
45
DELISTED
Allakos
ALLK
| – | – | -16,552,417 | Closed | -$3.77M |
|
46
CytomX Therapeutics
CTMX
$336M
| – | – | -5,228,461 | Closed | -$3.32M |
|
|
47
Galapagos
GLPG
$2.07B
| – | – | -1,454,422 | Closed | -$36.5M |
|
|
48
iTeos Therapeutics
ITOS
| – | – | -3,075,000 | Closed | -$18.4M |
|
49
NewAmsterdam Pharma
NAMS
$2.71B
| – | – | -59,065 | Closed | -$1.21M |
|
|
THRD
50
DELISTED
Third Harmonic Bio
THRD
| – | – | -2,372,933 | Closed | -$8.23M |
|